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Abstract The objective of this study is to examine the
efﬁcacy and tolerability of miglitol with respect to
improving glycemic control in Chinese patients with type 2
diabetes mellitus inadequately controlled by diet and sul-
fonylurea treatment. This was a randomized, double-blin-
ded, placebo-controlled, multicenter study. A total of 105
patients were randomized to receive 24 weeks of treatment
with miglitol (n = 52; titrated from 50 mg to 100 mg 3
times daily) or placebo (n = 53). Concomitant sulfonyl-
urea treatment and diet remained unchanged. The primary
endpoint was change in glycated hemoglobin (HbA1c)
from baseline at 24 weeks. Secondary endpoints were
changes in fasting plasma glucose (FPG), postprandial
plasma glucose (PPG), and postprandial serum insulin
(PSI). The miglitol treatment group showed signiﬁcantly
greater reductions in HbA1c and PPG levels compared with
the placebo group. With respect to adverse events,
abdominal discomfort, diarrhea, and hypoglycemia occur-
red with similar frequency in both groups. Results of this
study indicate that miglitol signiﬁcantly improves meta-
bolic control in Chinese patients with type 2 diabetes
mellitus. Miglitol is safe and well tolerated, with the
exception of abdominal discomfort. Therefore, miglitol
may be a useful adjuvant therapy for Chinese patients with
type 2 diabetes mellitus inadequately controlled by diet and
sulfonylurea treatment.
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Introduction
Diabetes mellitus, a rapidly growing health problem in
many countries, is an important cause of morbidity and
mortality. According to the US Centers for Disease Control
and Prevention, approximately 14.7 million people in the
United States were diagnosed with diabetes as of 2004, with
type 2 diabetes accounting for approximately 90% of those
cases [1]. Type 2 diabetes has resulted in an extremely large
and growing economic burden. Despite the availability of
effective diabetes-speciﬁc therapies, achievement of gly-
cemic goals by patients is far from adequate in the United
States. Less than half of adults with diabetes are reported to
attain a glycated hemoglobin (HbA1c) level of \7% [2].
From 1960 to 1988 in Taiwan, mortality ascribed to dia-
betes increased 6.3-fold [3]. In another study from Taiwan,
with a total of 1,124,348.4 person-years of follow-up,
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rate was 39.0/1,000 person-years [4].
Maintaining a normal plasma glucose level is key for
reducing the risk of developing complications of diabetes
[5]. Current recommendations from the UK Prospective
Diabetes Study Group emphasize lifestyle management,
diet, and exercise as the ﬁrst-line approach, followed by
therapy with oral antidiabetic drugs, administered alone or
in combination [5]. Recent reviews of the literature conﬁrm
the salutary effects of exercise in individuals with type 2
diabetes [6, 7]. Other standard therapies include the use of
peroxisome proliferator-activated receptor (PPAR)-gamma
agonists (thiazolidinediones), which decrease levels of
glycated hemaglobin, fasting plasma glucose, insulin, and
free fatty acids in patients with type 2 diabetes [8, 9],
and insulin, together with metformin, which acts predomi-
nantly to inhibit hepatic glucose production, or with insulin
secretagogues [10, 11]. Antidiabetic drug monotherapy
eventually necessitates the use of increasing dosage and/or
a second antidiabetic medication because type 2 diabetes
worsens over time as a result of declining pancreatic b-cell
function [12].
The class of a-glucosidase inhibitors has a unique mode
of action. These drugs block oligosaccharide catabolism,
delay carbohydrate digestion and absorption, and smooth
and lower postprandial plasma glucose (PPG) peaks [13,
14]. Miglitol is the ﬁrst pseudomonosaccharide a-glucosi-
dase inhibitor derived from 1-deoxynojirimycin and is
structurally a glucose analogue [15]. Its efﬁcacy, in
monotherapy [16] or in combination with sulfonylureas
[17], as a glucose-lowering agent in Chinese patients with
type 2 diabetes has not been determined in clinical studies.
The aim of this study was to investigate the efﬁcacy and
tolerability of miglitol in combination with sulfonylureas,
compared to sulfonylurea monotherapy, for the improve-
ment of glycemic control in Chinese outpatients with type
2 diabetes mellitus inadequately controlled by diet and
sulfonylurea treatment.
Patients and methods
Patients
The study design was a randomized, double-blinded,
placebo-controlled, multicenter comparison of miglitol
treatment compared with placebo administration over a
24-week period. Patients with a conﬁrmed diagnosis of
type 2 diabetes mellitus whose previous treatment with diet
and sulfonylureas had proved inadequate according to
medical chart monitoring were recruited at 4 medical
centers in Taiwan. Inclusion criteria included age
[20 years; fasting plasma glucose (FPG) concentration of
100 mg/dL to 240 mg/dL; HbA1c value of 6.5% (based on
the glycemic goal for adults of B6.5% as speciﬁed by the
Diabetes Association of Taiwan) to 10.0%; history of
uncontrolled type 2 diabetes mellitus despite prior nutrition
therapy; and stable dosing with a sulfonylurea for at least
8 weeks before randomization.
Exclusion criteria included the following: suggested
diagnosis of type 1 diabetes mellitus; active insulin ther-
apy, known lactose intolerance, or treatment with medi-
cation that signiﬁcantly alters gastrointestinal motility and/
or absorption; concomitant glucocorticoid therapy, other
medication affecting glucose homeostasis, or treatment
with investigational drugs; serum transaminase level[2.5
times the upper normal limit or serum creatinine level
[1.5 mg/dL; presence of signiﬁcant disease or condition
(including emotional disorder or substance abuse) that
would likely alter the course of diabetes or the patient’s
ability to complete the study; documented gastrointestinal
disease associated with marked disorder of digestion or
absorption, or condition that may worsen as a result of
increased gas formation in the intestine; pregnant or lac-
tating women or women of childbearing age without a
medically approved method of contraception; and patients
participating in another clinical trial within 90 days of
screening.
This study was conducted in accordance with the
European Community guidelines for Good Clinical Prac-
tice and the Declaration of Helsinki and its amendments.
The protocol was approved by the corresponding Joint
Institutional Review Board or the Department of Health
and Ethics Committee of each investigational site. Written
informed consent was obtained from each patient.
Study design and drug regimen
Patients with uncontrolled diabetes despite nutrition ther-
apy and sulfonylurea treatment were assigned to a 2-week
baseline work-up and dietary run-in period. During this
period, demographic data were obtained, and vital signs
and routine laboratory variables were measured. To con-
ﬁrm adherence to nutrition therapy, patients were instruc-
ted to complete a 3-day diet record before visit 2. Eligible
patients were randomized to receive miglitol (Migbose;
Standard Chem. & Pharm. Co., Ltd.) 50 mg 3 times daily
for 12 weeks, titrated to 100 mg 3 times daily for
12 weeks, or placebo. After randomization, patients were
instructed to complete a 3-day diet record before each visit.
Patients were asked to adhere to a dietary plan tailored to
their energy requirements and metabolic control, according
to current American Diabetes Association recommenda-
tions: carbohydrates up to 60%, fat \30%, and protein
12–20%. Concomitant sulfonylurea treatment remained
unchanged throughout the study.
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123Patients were instructed to take 1 miglitol or placebo
tablet with the ﬁrst mouthful of food at each of 3 main
daily meals. Drug compliance was determined by tablet
count at each visit. After randomization (week 0), patients
were assessed at weeks 4, 8, 12, 16, 20, and 24. A physical
examination, assessment of adverse events, dietary coun-
seling, and measurement of HbA1c were carried out at
each visit. All secondary efﬁcacy variables and routine
laboratory variables were measured at baseline obtained
before week 0 during the run-in period and at week 24. In
cases of premature termination, routine laboratory vari-
ables were measured at the last visit. Dose titration at week
12 was performed at the discretion of the investigator.
Patients with good tolerance to miglitol 50 mg 3 times
daily were titrated to 100 mg 3 times daily. Patients with
unsatisfactory, but acceptable, tolerance to the treatment
were maintained at 50 mg 3 times daily. Patients unable to
tolerate the treatment were discontinued from the study.
Patients reported to the study station between 08:00 and
08:30 AM after a 12-h fast. After emptying the bladder,
body height and weight were measured, and body mass
index (BMI) was calculated as body weight (kg) divided by
height squared (m
2). An electrocardiogram was performed
for all patients to evaluate cardiac function. The antecubital
vein of the arm was cannulated for blood sampling.
Baseline or fasting blood samples were obtained after
approximately 10 min of rest after cannula placement.
Laboratory methods
Venous blood samples were placed into individual tubes
with ethylenediaminetetraacetic acid. Aliquots of serum
and plasma were stored at -80C. Samples from each
patient were measured in the same assay to reduce inter-
assay variation. Hematology, biochemical assays (sodium,
potassium, serum creatinine, alkaline phosphatase, alanine
aminotransferase [ALT], aspartate aminotransferase [AST],
total protein), and lipid assays (triglyceride, total choles-
terol, low-density lipoprotein cholesterol [LDL-C], high-
density lipoprotein cholesterol [HDL-C]) were carried out
by routine automated methods. Plasma glucose was
detected by the glucose oxidase method with a 2300 STAT
glucose analyzer (Yellow Springs Instrument Inc., Yellow
Springs, OH). Serum insulin was determined by micro-
particle enzyme immunoassay with an AxSYM system
(Abbott Laboratories, Abbott Park, IL). Measurement of
HbA1c was performed with a DCA 2000 analyzer (Bayer
Diagnostics, Elkhart, IN).
Efﬁcacy and safety assessments
Intent-to-treat (ITT) analysis was performed for assess-
ment of efﬁcacy. Patients were included in the ITT
analysis if they had efﬁcacy data at baseline (week 0)
and at least 1 postbaseline efﬁcacy measurement. The
primary efﬁcacy variable was HbA1c concentration. The
endpoint was deﬁned as the last available measurement.
Secondary efﬁcacy variables included FPG, PPG, and
postprandial serum insulin (PSI). Venous blood for
postprandial measurements was taken 2 h after a standard
breakfast.
Patients were included in the safety analysis if they had
taken at least 1 dose of medication and had at least 1
postbaseline safety measurement. The baseline for safety
analysis was deﬁned as measurements taken at visit 1 (week
2), and the endpoint was deﬁned as the last measurements
taken at visit 8 (week 24). Safety variables were analyzed
descriptively. All adverse events were deﬁned according to
the Coding Symbols for a Thesaurus of Adverse Reaction
Terms (COSTART) glossary and body system categories
(http://hedwig.mgh.harvard.edu/biostatistics/ﬁles/costart.
html).
Safety and tolerance were assessed primarily from
spontaneously reported adverse events and described by the
patients at each visit, with special attention to the severity
of hypoglycemia; occurrences of symptoms suggestive of
hypoglycemia were recorded in the patient’s diary. These
symptoms were rated as grade 1 (mild and transient), grade
2 (transient inability to pursue usual activities), grade 3
(need for external assistance), or grade 4 (need for medical
assistance). Hypoglycemia was deﬁned as at least 1 episode
of symptoms suggestive of hypoglycemia during the study
period. Other adverse events were also recorded in the
patient’s diary. Serious adverse events were deﬁned as
events resulting in persistent or signiﬁcant disability or
incapacity, new hospitalization or prolongation of current
hospitalization, severe hypoglycemia, and life-threatening
events or death. Acute intoxication, important medical
events, and pregnancy were considered serious adverse
events.
Statistical analysis
Data are shown as mean ± standard deviation (SD) for
continuous variables and as n (%) for categorical variables
for demographics and adverse events follow-up. Data are
shown as mean ± standard error for change from baseline
for primary efﬁcacy endpoints. The last observation carried
forward (LOCF) approach was used for evaluation of pri-
mary efﬁcacy endpoints in the ITT population. For com-
parison of baseline demographics and change in efﬁcacy
endpoints from baseline, a 2-sample t test was performed
for continuous variables, and chi-square or Fisher exact test
was performed for categorical variables. Nonparametric
Wilcoxon rank-sum test was also performed if the contin-
uous data were not normally distributed. Data analysis was
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NC). Differences were considered statistically signiﬁcant at
P\0.05.
Results
Patient disposition is detailed in Fig. 1. A total of 138
patients with type 2 diabetes mellitus inadequately con-
trolled by diet and sulfonylurea treatment were screened. A
total of 105 patients were eligible for randomization; 52
were assigned to receive miglitol treatment, and 53 were
assigned to receive placebo. Efﬁcacy endpoints were ana-
lyzed in the ITT population, regardless of protocol com-
pliance, and adverse events were followed-up in the safety
population. Of the 105 patients, 100 (49 in the miglitol
group and 51 in the placebo group) comprised the ITT
population; 5 patients failed to return for postclinical
assessment. All 105 randomized patients received treat-
ment and were followed up for safety.
Baseline demographic and clinical characteristics of
patients in the ITT population, listed by treatment group,
are presented in Table 1. There were no signiﬁcant dif-
ferences in demographic or other baseline characteristics
between the miglitol and placebo groups. Table 2 shows
results for changes from baseline for the efﬁcacy variables
HbA1c, FPG, PPG, and PSI at week 24 in the ITT popu-
lation. The change in HbA1c from baseline for the miglitol
group was -0.85% ± 0.12% compared to -0.19% ±
0.11% for the placebo group (P\0.001). There was also a
signiﬁcant difference in the change in PPG between groups
(P\0.001). No signiﬁcant difference in change in FPG
(P = 0.052) or PSI (P = 0.364) was found between
groups. The change in ALT from baseline for the miglitol
group was 8.40 ± 7.20 U/L compared to 2.29 ± 6.66 U/L
for the placebo group (P = 0.009). For both groups, ﬁnd-
ings for ALT were similar between baseline and week 24
(visit 8) in terms of median, SD, and range; however, the
mean value was signiﬁcantly increased in the miglitol
group, owing to a single patient with underlying chronic
hepatitis and fatty liver.
Glycemic control in the ITT population, as measured by
HbA1c level, showed signiﬁcant improvement in both the
miglitol and placebo groups compared to baseline (week 0)
after 12 weeks (P\0.01), 16 weeks (P\0.01), 20 weeks
(P\0.001), and 24 weeks (P\0.001) (Fig. 2). In addi-
tion, the decrease from baseline to 24 weeks in HbA1c was
signiﬁcantly higher in the miglitol group than in the
placebo group (P\0.001).
Among the 105 patients, 49 (94.2%) in the miglitol
group and 42 (79.3%) in the placebo group experienced at
least 1 adverse event during the study period. A total of 59
and 39 adverse events occurred in the miglitol and placebo
groups, respectively. Table 3 shows the most frequent
adverse events, which included abdominal discomfort,
diarrhea, hypoglycemia, and other. Patients in the miglitol
group reported other adverse events signiﬁcantly more
often than did those in the placebo group (P = 0.036). No
major episodes requiring external assistance were reported.
No clinically signiﬁcant changes in any of the hematologic
or clinical biochemistry variables were identiﬁed, and all
changes were within normal range, with the exception that
Fig. 1 Progress of patients
throughout the 24-week trial
period
74 Acta Diabetol (2011) 48:71–77
1234 patients (2 in the miglitol group, and 2 in the placebo
group) had elevated liver enzymes at the end of the study.
However, these same patients already had abnormal liver
enzyme levels at baseline. There were no signiﬁcant dif-
ferences between treatment groups with respect to vital
signs or results of physical examination, urinalysis, or
electrocardiography.
Discussion
The objective of the present study was to investigate the
efﬁcacy and tolerability of miglitol in combination with
sulfonylureas, compared to sulfonylurea monotherapy, for
the improvement of glycemic control in Chinese outpa-
tients with type 2 diabetes mellitus inadequately controlled
Table 1 Demographic and baseline clinical characteristics in 105 randomized patients with type 2 diabetes
Characteristic Total (N = 105) Miglitol (n = 52) Placebo (n = 53) P value
Age (years) 58.7 ± 10.5 58.4 ± 10.5 59.0 ± 10.7 0.759
Gender (M/F) 41/64 23/29 18/35 0.281
Body weight (kg) 68.2 ± 10.5 67.2 ± 10.3 69.2 ± 10.6 0.319
Height (cm) 162.8 ± 8.2 162.8 ± 8.1 162.8 ± 8.4 0.978
BMI (kg/m
2) 25.7 ± 3.0 25.3 ± 3.1 26.1 ± 2.9 0.201
HbA1c (%) 8.13 ± 0.74 8.14 ± 0.72 8.11 ± 0.77 0.893
FPG (mg/dL) 160.06 ± 29.69 165.13 ± 28.17 155.10 ± 30.57 0.093
PPG (mg/dL) 233.52 ± 66.42 246.76 ± 58.98 220.80 ± 71.12 0.050
PSI (lU/mL) 41.85 ± 32.28 40.59 ± 32.44 43.09 ± 32.38 0.496
Data are presented as mean ± standard deviation (SD) for all variables, with the exception of gender (n)
P values were determined by 2-sample t test, with the exception of PSI, which was assessed by nonparametric Wilcoxon rank-sum test
BMI Body mass index, HbA1c glycated hemoglobin, FPG fasting plasma glucose, PPG postprandial plasma glucose, PSI postprandial serum
insulin
Table 2 Changes in efﬁcacy endpoints from baseline by study group
in the intention-to-treat population (n = 100)
Characteristics
a, b Miglitol (n = 49) Placebo (n = 51) P value
c
HbA1c (%) –0.85 ± 0.12 –0.19 ± 0.11 \0.001
d
FPG (mg/dL) –13.44 ± 5.48 –0.20 ± 3.91 0.052
PPG (mg/dL) –44.8 ± 10.43 14.07 ± 9.47 \0.001
d
PSI (lU/mL) –4.53 ± 3.91 –3.78 ± 5.34 0.364
AST (SGOT, U/L) 1.96 ± 3.66 –1.5 ± 1.23 0.888
ALT (SGPT, U/L) 8.40 ± 7.20 2.29 ± 6.66 0.009
d
HDL-C –0.50 ± 1.67 –2.91 ± 1.39 0.861
LDL-C 0.81 ± 3.84 –9.36 ± 2.90 0.037
d
TG –31.15 ± 11.16 –2.96 ± 12.97 0.156
Total cholesterol 0.042 ± 4.11 –7.0 ± 3.31 0.185
a Data were presented as mean ± standard error (SE)
b HbA1c Glycated hemoglobin, FPG fasting plasma glucose, PPG
postprandial plasma glucose, PSI postprandial serum insulin, AST
aspartate aminotransferase, ALT alanine aminotransferase, HDL high-
density lipoprotein cholesterol, LDL low-density lipoprotein choles-
terol, TG triglyceride
c P values for estimation of differences between change in miglitol
and placebo groups from baseline were assessed by 2-sample t test for
HbA1c, FPG, and PPG and by nonparametric Wilcoxon rank-sum test
for PSI, AST, ALT, HDL, LDL, and TG
d P\0.05 indicated that the change from baseline of efﬁcacy end-
point was signiﬁcantly different between the miglitol and placebo
treatment groups
Fig. 2 Glycated hemoglobin levels for each study group in the intent-
to-treat population (N = 100) during the 24-week trial period.
**P\0.01, ***P\0.001
Table 3 Most frequent adverse events by study group in the safety
population (n = 105)
Adverse event* Miglitol
(n = 59)
Placebo
(n = 39)
P value
Abdominal discomfort
 10 (16.95) 2 (5.13) 0.084
Diarrhea
 20 (33.90) 7 (17.95) 0.117
Hypoglycemia
 20 (33.90) 17 (43.59) 0.333
Other
 9 (15.25) 13 (33.33) 0.036
§
* Data are presented as n (%) of all adverse events compared with
 Chi-square or
 Fisher exact test
§ P values\0.05 indicate that the incidence of a speciﬁc adverse
event was signiﬁcantly different between the 2 groups
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123by diet and sulfonylurea treatment. The primary endpoint
was change from baseline in HbA1c concentration at week
24. Results showed a greater than fourfold difference
between the change in HbA1c from baseline in the miglitol
group compared with the placebo group, with the differ-
ence between the 2 groups reaching statistical signiﬁcance
at week 12 (P\0.01). Clinically signiﬁcant effects of
miglitol treatment were found from weeks 12 to 24. This
result corresponded well with decreases in HbA1c reported
in another study of miglitol adjuvant therapy [18].
The HbA1c concentration reﬂects long-term glycemic
control [19], and a decrease in HbA1c results in a reduced
risk of microvascular adverse events [5]. A major problem
in the use of oral antidiabetic drugs, such as sulfonylureas,
is the gradual decrease in the ability of these drugs to
satisfactorily control blood glucose level [20]. Pharmaco-
logic agents are available that modify primarily the PPG
level to reduce serum HbA1c [21, 22]. a-Glucosidase
inhibitors produce an antihyperglycemic effect and do not
induce weight gain, a common problem encountered with
sulfonylureas and insulin [23]. A recent meta-analysis of
41 randomized trials examined the efﬁcacy of a-glucosi-
dase inhibitors in patients with type 2 diabetes and showed
no evidence of a beneﬁcial effect on morbidity or mortality
[24]. However, statistically signiﬁcant effects on HbA1c
(by acarbose), FPG (by miglitol), postload glucose, insulin
level, and BMI (by acarbose) were found. The study found
no effects on PSI or lipids and only minor effects on body
weight.
The clinical signiﬁcance of the regulation of postpran-
dial hyperglycemia in reducing the risk of microvascular
and macrovascular complications has been established in
several epidemiologic studies [25–27]. Results of the
present study are of interest because the PPG level was
signiﬁcantly decreased in the miglitol group compared with
the placebo group (P\0.001). With respect to lipid vari-
ables, we found no signiﬁcant differences between groups
in the present study, similar to previous results [24].
The major adverse effects of a-glucosidase inhibitors,
such as acarbose, include gastrointestinal symptoms; these
arise mainly from the fermentation of undigested carbo-
hydrates by colonic bacteria [28]. In contrast, miglitol is
absorbed systemically, but is not metabolized, and is
excreted into the urine within a relatively short period of
time. Consequently, systemic adverse effects are not
anticipated. Indeed, no systemic adverse effects occurred in
the present study. There was also no incidence of severe
hypoglycemia. The most common complaints in this study
were mild hypoglycemia, diarrhea, and abdominal dis-
comfort, resulting in premature termination of miglitol
treatment by 4 patients. Approximately half of the patients
in the miglitol group and 15.7% of the patients in the
placebo group experienced these symptoms.
Several case reports from Europe and Japan have indi-
cated that acarbose, a commonly prescribed a-glucosidase
inhibitor, can result in severe, but reversible, hepatotoxic-
ity, as indicated by markedly increased levels of AST and
ALT [29–31]. In contrast, treatment with miglitol at the
dosages used in the present study increased AST and ALT
to a much lesser extent (B1.8 times to upper limit of nor-
mal) [17]. Because of the relatively high prevalence of
hepatitis B and hepatitis C in Asian countries, the use of
miglitol may prove to be a better choice compared to
acarbose with respect to minimizing hepatic effects.
The small number of cases and the relatively short,
24-week study period are potential limitations of the
present study. Future large-scale studies are needed to
assess the long-term cardiovascular and glucose-control
effects of miglitol.
Conclusions
Results of the present study indicate that miglitol improved
PPG level and glycemic control, as reﬂected by decreased
HbA1c concentration in Chinese patients with type 2 dia-
betes mellitus. Miglitol was well tolerated, with no unusual
changes in safety proﬁles, with the exception of abdominal
discomfort during the 24-week treatment period. There-
fore, miglitol may be a useful adjuvant therapy for Chinese
patients with type 2 diabetes inadequately controlled by
diet and sulfonylurea treatment.
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